#China #Shanghai #bispecific antibody #Harbour BioMed #HBM7004

Harbour BioMed Gains Approval for HBM7004

Harbour BioMed, a leading global biopharmaceutical company, proudly announces that its Investigational New Drug (IND) application for HBM7004 has received approval from the National Medical Products Administration (NMPA) in China. This pivotal development marks a significant step forward in the ongoing fight against advanced solid tumors, signaling potential new therapeutic avenues for patients with limited treatment options.

Introduction to HBM7004

HBM7004 is a state-of-the-art bispecific antibody developed using Harbour BioMed's proprietary HBICE® platform. This platform has distinguished itself in the field of immunotherapy by facilitating the development of innovative cancer treatments. The unique structure of HBM7004 targets both B7H4 and CD3, offering a novel approach to activate T cells specifically within the tumor microenvironment. In preliminary studies, HBM7004 has shown promising results, illustrating its ability to selectively activate T cells in a B7H4-dependent manner, directly within tumors.

Preclinical Successes

The advancement of HBM7004 from the lab to clinical trials is underpinned by robust preclinical evidence. Multiple animal models have demonstrated powerful anti-tumor efficacy, showcasing stability within the body alongside minimized systemic toxicity. Notably, the bispecific antibody exhibited a synergistic effect when it was combined with another bispecific antibody targeting B7H4 and 4-1BB, even at low doses of effector cells. These findings underscore the promising therapeutic window HBM7004 offers, suggesting it could be a game-changer for oncological treatment regimens.

Statement from Harbour BioMed

Dr. Jingsong Wang, Founder and CEO of Harbour BioMed, expressed his enthusiasm about the NMPA's approval, stating, "We are very pleased to receive NMPA approval for HBM7004, marking a crucial milestone in our mission to advance innovative immunotherapies. This, combined with recent FDA clearance, confirms the strength of our HBICE® platform in creating differentiated bispecific candidates with encouraging preclinical results. We are now on the brink of bringing HBM7004 into the clinical setting in China, aiming to meet the needs of cancer patients where treatment options are limited."

A Look at Harbour BioMed

Founded with the mission to revolutionize biopharmaceutical development, Harbour BioMed specializes in the discovery and production of novel antibody therapies. Utilizing advanced technologies, such as the Harbour Mice® platform for generating fully human monoclonal antibodies, the company is well-positioned to push this innovative treatment approach forward. By integrating various platforms, including HBICE® and HCAb PLUSTM, Harbour BioMed is creating a distinctive portfolio across several disease areas.

With a rigorous commitment to research and development, Harbour BioMed is not only dedicated to creating effective treatments but also aims to streamline drug development through strategic collaborations and selective acquisitions. As they continue to adapt to the complex landscape of biotechnology, the company’s focus on innovation stays at the forefront of their operations, evidenced by their newly launched AI model, powered by their proprietary Hu-mAtrIxTM.

The Future of Cancer Treatment

As Harbour BioMed prepares to initiate clinical trials for HBM7004, the biopharmaceutical landscape is poised for transformation. With advanced solid tumors being notoriously difficult to treat, effective therapies such as HBM7004 could significantly enhance patient outcomes. The company’s commitment to pioneering antibody therapies reinforces its role as a leader in the fight against cancer, ultimately aiming to provide hope to countless individuals worldwide.

In conclusion, the NMPA's approval for HBM7004 not only represents a remarkable achievement for Harbour BioMed but also stands as a testament to the potential that innovative biopharmaceuticals hold in transforming cancer therapy as we know it.